Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Sgroi

Showing results (71-80 of 113) with videos related to

Pageof 12
Sort By:
Breast Cancer Research and Treatment|October 24, 2018
Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence scorePiiha-Lotta Jerevall, Jane Brock, Juan Palazzo, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2006
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Gromoslaw A Smolen, Raffaella Sordella, Beth Muir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohortBen S Wittner, Dennis C Sgroi, Paula D Ryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2006
Prospective study of wide excision alone for ductal carcinoma in situ of the breastJulia S Wong, Carolyn M Kaelin, Susan L Troyan, et al.
Breast Cancer Research and Treatment|December 19, 2013
Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS)Julia S Wong, Yu-Hui Chen, Michele A Gadd, et al.
Breast Cancer Research : BCR|December 16, 2022
Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom studyDennis C Sgroi, Kai Treuner, Yi Zhang, et al.
Breast Cancer Research : BCR|January 6, 2016
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 studyDennis C Sgroi, Judy-Anne W Chapman, T Badovinac-Crnjevic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifenMatthew P Goetz, Vera J Suman, James N Ingle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular CarcinomaRaquel Nunes, Tal Sella, Kai Treuner, et al.
Cancer Research|November 20, 2002
Proteomics of human breast ductal carcinoma in situJulia D Wulfkuhle, Dennis C Sgroi, Henry Krutzsch, et al.
Pageof 12

Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
Breast Cancer Research and Treatment|October 24, 2018
Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence scorePiiha-Lotta Jerevall, Jane Brock, Juan Palazzo, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2006
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Gromoslaw A Smolen, Raffaella Sordella, Beth Muir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohortBen S Wittner, Dennis C Sgroi, Paula D Ryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2006
Prospective study of wide excision alone for ductal carcinoma in situ of the breastJulia S Wong, Carolyn M Kaelin, Susan L Troyan, et al.
Breast Cancer Research and Treatment|December 19, 2013
Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS)Julia S Wong, Yu-Hui Chen, Michele A Gadd, et al.
Breast Cancer Research : BCR|December 16, 2022
Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom studyDennis C Sgroi, Kai Treuner, Yi Zhang, et al.
Breast Cancer Research : BCR|January 6, 2016
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 studyDennis C Sgroi, Judy-Anne W Chapman, T Badovinac-Crnjevic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifenMatthew P Goetz, Vera J Suman, James N Ingle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular CarcinomaRaquel Nunes, Tal Sella, Kai Treuner, et al.
Cancer Research|November 20, 2002
Proteomics of human breast ductal carcinoma in situJulia D Wulfkuhle, Dennis C Sgroi, Henry Krutzsch, et al.
Pageof 12